TMX Newsfile Healthcare and Hospitals News Releases

TelyRx to Host Second Quarter 2026 Financial Results Conference Call on Monday, August 10, 2026 at 8:30 am ET

Fri, 24 Jul 2026 07:35:00 -0400

Clearwater, Florida--(Newsfile Corp. - July 24, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced it will host a conference call and webcast to discuss its second quarter 2026 financial results on Monday, August 10, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its second quarter 2026 financial results for the period ended June 30, 2026,...

LDIC Inc. Announces the Termination of the Healthcare Special Opportunities Fund

Thu, 23 Jul 2026 17:01:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 23, 2026) - LDIC Inc. (TSX: MDS.UN) (the "Manager") today announced that it will pursue the termination of the Healthcare Special Opportunities Fund (the "Fund") to be effected in the third quarter of 2026 (the "Termination"), subject to obtaining the necessary approvals from the unitholders and regulatory authorities.The Manager has reviewed the current size of the Fund, its management expense ratio, its portfolio composition including its holdings of...

Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance

Thu, 23 Jul 2026 01:01:00 -0400

Ad hoc announcement pursuant to Art. 53 LR Recurring revenues from Winlevi® up 38%, Lialda® up 35%, and CDMO up 14% year-over-year Clascoterone Phase III 12-month data support chronic use, with regulatory submissions underway in the US and in Europe Debt-free with more than €205 million in cash, cash equivalents and investments Investor call today at 3 pm CET Dublin, Ireland--(Newsfile Corp. -...

medmix Strengthens Profitability and Cash Flow While Advancing Growth and Efficiency Initiatives

Thu, 23 Jul 2026 00:09:00 -0400

Baar, Switzerland--(Newsfile Corp. - July 23, 2026) - Ad hoc announcement pursuant to Art. 53 LR MEDIA RELEASE Ad hoc announcement pursuant to Art. 53 LR Half-Year 2026 Results DOWNLOAD MEDIA RELEASE HALF-YEAR 2026 HIGHLIGHTS Revenue...

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 12:30:00 -0400

King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous...

Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Canada

Wed, 22 Jul 2026 10:00:00 -0400

Moncton, New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - July 22, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that Vitalité Health Network has joined as the first Canadian site in its large multi-center observational data collection study to advance the development of its technology for the early detection of breast cancer in breath for women with dense breasts, as an adjunct to mammography.The study is...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 07:00:00 -0400

Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial

Tue, 21 Jul 2026 09:17:00 -0400

White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company continues to build...

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Tue, 21 Jul 2026 07:00:00 -0400

King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, and former FDA advisory...

Bachem Plans to Build a Large-Scale Production Facility in Sisslerfeld

Tue, 21 Jul 2026 00:40:00 -0400

Ad hoc announcement pursuant to Art. 53 LR The next phase of the greenfield project in Sisslerfeld (Eiken, Switzerland) will be implemented as part of a strategic collaboration. Total investment amounts to more than CHF 500 million. Start of commercial production at the new site is expected in 2030. Bubendorf, Switzerland--(Newsfile Corp. - July 21, 2026) - Bachem (SIX: BANB) announced today the signing of an agreement to supply large volumes...